Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
India's Sun Pharma aims to launch its obesity drug in five years, managing director says
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...
Becker's Hospital Review5d
FDA sets deadline to end sales of Ozempic, Wegovy copycats
Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...
Daily9h
Sun Pharma eyes to launch obesity drug in five years: MD
Mumbai: Pharma major, Sun Pharmaceutical, is gearing up to introduce its experimental anti-obesity and type 2 diabetes ...
Healthline11d
Ozempic vs. Trulicity: What You Should Know
A generic drug is an exact copy of the active ... for certain conditions is prescribed for another purpose.) Wegovy, a drug that is FDA approved for weight loss, has the same active ingredient ...
The Cincinnati Enquirer7d
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Feb 21 (Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's NOVOb.CO popular weight-loss and diabetes drugs, Wegovy and ...